A Phase 3 clinical trial evaluating Retatrutide for the treatment of Type 2 Diabetes completed its primary data collection on January 22, 2026. This study, known as TRANSCEND-T2D-1, investigated the efficacy and safety of the drug compared to placebo.
Background
Retatrutide is an investigational drug being studied for its potential in managing Type 2 Diabetes. This condition affects millions globally and is characterized by inadequate glycemic control, often requiring therapeutic interventions beyond diet and exercise.
Trial design
The completed Phase 3 trial, NCT06354660, titled "Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)", enrolled 537 adult participants. The study focused on individuals with Type 2 Diabetes who had inadequate glycemic control despite diet and exercise. Participants were randomized to receive either retatrutide or placebo to assess the drug's efficacy and safety.
What this means
The primary completion of the TRANSCEND-T2D-1 trial signifies a key milestone in the development of retatrutide for Type 2 Diabetes. While specific efficacy and safety results are not yet available, the completion of data collection moves the study closer to potential data analysis and reporting, which will provide insights into the drug's performance.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06354660, indicating primary completion, was posted on January 22, 2026, on clinicaltrials.gov.